Clinical Research Directory

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Alveltamig and Atezolizumab for Adults Participants With Extensive Stage-Small Cell Lung Cancer

Sponsor: AbbVie

Summary

Small cell lung cancer (SCLC) is a type of lung cancer that accounts for approximately 15-17% of all lung cancers. It is characterized by aggressive and rapid growth and early spread to distant sites. Extensive stage-small cell lung cancer (ES-SCLC) includes cases where disease has spread beyond one side of the chest. This study will evaluate the safety and efficacy of ABBV-706 in combination with atezolizumab and alveltamig in previously untreated ES-SCLC. ABBV-706 and alveltamig are investigational drugs being developed for the treatment of ES-SCLC. This is an open-label study, meaning participants and doctors know which treatment is being given. Participants are placed into 1 of 2 treatment arms. Each arm receives a different dose of ABBV-706 in combination with alveltamig and atezolizumab. Adult participants with a diagnosis of previously untreated extensive stage-small cell lung cancer will be enrolled. Around 80 participants will be enrolled in the study at approximately 25 sites worldwide. Participants will receive intravenous (IV) infusion of ABBV-706 in combination with IV infusion of atezolizumab and IV infusion of alveltamig. The estimated duration of the study is approximately 61 months. There may be higher treatment burden for participants in this trial compared to their standard of care due to study procedures. Participants will attend regular visits during the study at a hospital or clinic. The effects of the treatment will be checked by medical assessments, blood tests, imaging scans, checking for side effects and completing questionnaires.

Official title: A Phase 2, Open-label, Randomized Study to Evaluate the Safety and Efficacy of ABBV-706 in Combination With Alveltamig and Atezolizumab in First-Line in Subjects With Extensive Stage-Small Cell Lung Cancer (ES-SCLC)

Key Details

Conditions

Interventions